Loading...
Loading...
ANTX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 8,598.0K |
| Operating I/L | -8,598.0K |
| Other Income/Expense | 1,076.0K |
| Interest Income | 0.0K |
| Pretax | -7,522.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -7,522.0K |
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing treatments for rare, chronic, and serious infectious diseases. Their primary focus is on the development of epetraborole, a once-daily oral treatment designed for patients suffering from chronic non-tuberculous mycobacterial lung disease. The company's revenue model is centered around the research, development, and commercialization of innovative pharmaceutical solutions to address unmet medical needs in the infectious disease space.
